|
article-title
|
Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries
|
|
abstract
|
Background
Increasing evidence suggests pernio-like lesions are cutaneous manifestations of coronavirus infectious disease 2019 (COVID-19).
Objective
To describe clinical and pathologic findings of pernio-like lesions in patients with confirmed or suspected COVID-19.
Methods
An international dermatology registry was circulated to health care providers worldwide through the American Academy of Dermatology, International League of Dermatologic Societies, and other organizations.
Results
We documented 505 patients with dermatologic manifestations associated with COVID-19, including 318 (63%) with pernio-like lesions. Patients with pernio-like lesions were generally young and healthy, with relatively mild COVID-19. Of 318 patients with confirmed or suspected COVID-19 by providers, 23 (7%) were laboratory-confirmed COVID-19 positive, and 20 others (6%) were close contacts of patients with confirmed COVID-19. Given current testing criteria, many patients lacked COVID-19 testing access. For 55% of patients, pernio-like lesions were their only symptom. In patients with other COVID-19 symptoms, pernio-like lesions typically appeared after other symptoms. Pernio-like lesions lasted a median of 14 days (interquartile range, 10-21 days).
Limitations
A case series cannot estimate population-level incidence or prevalence. In addition, there may be confirmation bias in reporting. We cannot exclude an epiphenomenon.
Conclusions
Pernio-like skin changes of the feet and hands, without another explanation, may suggest COVID-19 infection and should prompt confirmatory testing.
|
|
sec
|
Background
Increasing evidence suggests pernio-like lesions are cutaneous manifestations of coronavirus infectious disease 2019 (COVID-19).
|
|
title
|
Background
|
|
p
|
Increasing evidence suggests pernio-like lesions are cutaneous manifestations of coronavirus infectious disease 2019 (COVID-19).
|
|
sec
|
Objective
To describe clinical and pathologic findings of pernio-like lesions in patients with confirmed or suspected COVID-19.
|
|
title
|
Objective
|
|
p
|
To describe clinical and pathologic findings of pernio-like lesions in patients with confirmed or suspected COVID-19.
|
|
sec
|
Methods
An international dermatology registry was circulated to health care providers worldwide through the American Academy of Dermatology, International League of Dermatologic Societies, and other organizations.
|
|
title
|
Methods
|
|
p
|
An international dermatology registry was circulated to health care providers worldwide through the American Academy of Dermatology, International League of Dermatologic Societies, and other organizations.
|
|
sec
|
Results
We documented 505 patients with dermatologic manifestations associated with COVID-19, including 318 (63%) with pernio-like lesions. Patients with pernio-like lesions were generally young and healthy, with relatively mild COVID-19. Of 318 patients with confirmed or suspected COVID-19 by providers, 23 (7%) were laboratory-confirmed COVID-19 positive, and 20 others (6%) were close contacts of patients with confirmed COVID-19. Given current testing criteria, many patients lacked COVID-19 testing access. For 55% of patients, pernio-like lesions were their only symptom. In patients with other COVID-19 symptoms, pernio-like lesions typically appeared after other symptoms. Pernio-like lesions lasted a median of 14 days (interquartile range, 10-21 days).
|
|
title
|
Results
|
|
p
|
We documented 505 patients with dermatologic manifestations associated with COVID-19, including 318 (63%) with pernio-like lesions. Patients with pernio-like lesions were generally young and healthy, with relatively mild COVID-19. Of 318 patients with confirmed or suspected COVID-19 by providers, 23 (7%) were laboratory-confirmed COVID-19 positive, and 20 others (6%) were close contacts of patients with confirmed COVID-19. Given current testing criteria, many patients lacked COVID-19 testing access. For 55% of patients, pernio-like lesions were their only symptom. In patients with other COVID-19 symptoms, pernio-like lesions typically appeared after other symptoms. Pernio-like lesions lasted a median of 14 days (interquartile range, 10-21 days).
|
|
sec
|
Limitations
A case series cannot estimate population-level incidence or prevalence. In addition, there may be confirmation bias in reporting. We cannot exclude an epiphenomenon.
|
|
title
|
Limitations
|
|
p
|
A case series cannot estimate population-level incidence or prevalence. In addition, there may be confirmation bias in reporting. We cannot exclude an epiphenomenon.
|
|
sec
|
Conclusions
Pernio-like skin changes of the feet and hands, without another explanation, may suggest COVID-19 infection and should prompt confirmatory testing.
|
|
title
|
Conclusions
|
|
p
|
Pernio-like skin changes of the feet and hands, without another explanation, may suggest COVID-19 infection and should prompt confirmatory testing.
|
|
body
|
Capsule Summary
• This large international registry-based case series adds to the emerging evidence that pernio-like lesions may be a cutaneous manifestation of COVID-19.
• Patients with pernio-like lesions generally had benign clinical courses. Importantly, because some of these patients may be infectious, isolation and COVID-19 testing must be considered.
Emerging evidence suggests that coronavirus infectious disease 2019 (COVID-19) has associated dermatologic manifestations. Many cutaneous findings of COVID-19 are nonspecific, such as morbilliform exanthems, urticarial eruptions, and vesicular lesions, and are often seen in the context of other viral infections.1, 2, 3 In contrast, recent reports from around the globe highlight a striking pernio-like phenomenon in association with COVID-19.1 , 4 , 5 Pernio, or chilblains, is a superficial inflammatory vascular response that occurs on acral skin, usually after cold exposure, typically in children and young to middle-aged women.6 In this large international registry-based case series, we evaluate clinical characteristics of patients with suspected or confirmed COVID-19 who presented with pernio-like lesions on acral surfaces. Our objectives were to assess location, timing, and duration of the pernio-like lesions, and to analyze patients' comorbidities, COVID-19 severity, and disease outcomes.
Methods
We established a registry to collect cases of COVID-19 with dermatologic manifestations reported by medical professionals, with data collected from April 8, 2020, to May 2, 2020. The registry was widely promoted to members of the American Academy of Dermatology, major dermatology subspecialty groups, the International League of Dermatologic Societies, and dermatology and general medicine groups on social media. The website (www.aad.org/covidregistry) was hosted through a Massachusetts General Hospital REDCap (Research Electronic Data Capture, Vanderbilt University, Nashville, TN) database. The registry queried patient demographics, dermatologic symptoms, COVID-19 history and symptoms, and past medical history. For this subanalysis, we included patients with new-onset pernio-like skin changes in the setting of confirmed or suspected COVID-19 and excluded patients with prior history of pernio. The deidentified patient data was analyzed using Stata 16 software (StataCorp, College Station, TX). The registry was reviewed by Partners Healthcare Institutional Review Board and was determined to not meet the definition of Human Subjects Research.
Results
The registry compiled 505 cases of dermatologic manifestations associated with COVID-19 over 25 days, reported by dermatologists (50%), other physicians (37%), and midlevel practitioners (8%). There were 318 patients (63%) identified with pernio-like changes in the setting of confirmed or suspected COVID-19 (Table I ). Patients were generally young and healthy, with median age of 25 years (interquartile range, 17-38 years), including 93 children and adolescents. Only 25% had medical comorbidities.
Table I Clinical characteristics of patients with confirmed and suspected COVID-19 who developed pernio-like lesions on acral skin
Characteristic∗ COVID-19 laboratory positive (n = 23)† Close contact with COVID-19 laboratory positive (n = 20) COVID-19 clinical suspicion (n = 229) COVID-19 PCR negative‡ (n = 46) Overall (n = 318)
Age, years 41 (23-57) 24 (17-37) 24 (17-37) 27 (16-36) 25 (17-38)
Female sex§ 11 (48) 5 (25) 118 (52) 21 (46) 155 (49)
Race/ethnicity‖
White 18 (86) 17 (94) 195 (91) 38 (83) 268 (89)
Asian 1 (4.8) 1 (5.6) 14 (6.5) 6 (13) 22 (7.3)
Black/African American 0 (0.0) 0 (0.0) 1 (0.5) 1 (2.2) 2 (0.7)
Hispanic/Latino 2 (9.5) 0 (0.0) 5 (2.3) 1 (2.2) 8 (2.7)
Country of residence
United States 22 (96) 17 (85) 212 (93) 42 (91) 293 (92)
Canada 0 (0.0) 1 (5.0) 6 (2.6) 4 (8.7) 11 (3.5)
France 0 (0.0) 1 (5.0) 4 (1.8) 0 (0.0) 5 (1.6)
United Kingdom 1 (4.3) 1 (5.0) 2 (0.9) 0 (0.0) 4 (1.3)
Italy 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Mexico 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Netherlands 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Iran 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Average monthly temperature‖
Above 10°C 4 (18) 1 (5.0) 66 (29) 20 (43) 91 (29)
Below 10°C 19 (82) 19 (95) 163 (71) 26 (57) 227 (71)
Body site affected
Foot 20 (87) 19 (95) 216 (94) 43 (93) 298 (94)
Hand 7 (30) 2 (10) 31 (14) 8 (17) 48 (15)
Dermatologic symptoms
Asymptomatic 4 (17) 2 (10) 24 (11) 6 (13) 36 (11)
Pain/burning 16 (70) 16 (80) 144 (63) 35 (76) 211 (66)
Pruritus 8 (35) 9 (45) 99 (43) 21 (46) 137 (43)
Cold intolerance 2 (8.7) 2 (10) 17 (7.4) 1 (2.2) 22 (6.9)
Timing of dermatologic changes
Before COVID-19 symptoms 4 (17) 0 (0.0) 12 (5.4) 3 (6.5) 19 (6.1)
After COVID-19 symptoms 11 (48) 6 (30) 48 (22) 15 (33) 80 (26)
At the same time as COVID-19 3 (13) 1 (5.0) 14 (6.3) 4 (8.7) 22 (7.1)
No other COVID-19 symptoms 5 (22) 12 (60) 132 (59) 21 (46) 170 (55)
Unknown 0 (0.0) 1 (5.0) 17 (7.6) 3 (6.5) 21 (6.7)
COVID-19 exposure
None (community acquired) 7 (30) 0 (0.0) 126 (55) 20 (43) 153 (48)
Close contact with patient with
Confirmed COVID-19 3 (13) 20 (100) 0 (0.0) 1 (2.1) 24 (7.5)
Suspected COVID-19 8 (35) 4 (20) 26 (11) 6 (13) 44 (14)
Presence in a health care facility where COVID-19 infections have been managed 1 (4.3) 0 (0.0) 10 (4.4) 7 (15) 18 (5.7)
COVID-19 symptoms
Asymptomatic 5 (22) 10 (50) 140 (61) 19 (41) 174 (55)
Cough 9 (39) 3 (15) 41 (18) 14 (30) 67 (21)
Headache 7 (30) 4 (20) 27 (12) 9 (20) 47 (15)
Sore throat 5 (22) 4 (20) 21 (9.2) 8 (17) 38 (12)
Fever 9 (39) 1 (5.0) 18 (7.9) 9 (20) 37 (12)
Malaise 4 (17) 1 (5.0) 20 (8.7) 6 (13) 31 (9.7)
Shortness of breath 6 (26) 1 (5.0) 16 (7.0) 6 (13) 29 (9.1)
COVID-19 level of care
Outpatient care only 18 (78) 20 (100) 229 (100) 45 (98) 312 (98)
Hospitalized, alive 3 (13) … … 1 (2.2) 4 (1.3)
Hospitalized, died 2 (8.7) … … … 2 (0.6)
Comorbid medical conditions
None 17 (74) 12 (60) 172 (75) 36 (78) 237 (75)
Obstructive lung disease 2 (8.7) 2 (10) 12 (5.2) 1 (2.2) 17 (5.3)
Hypertension 2 (8.7) 1 (5.0) 5 (2.2) 1 (2.2) 9 (2.8)
Rheumatologic disease 2 (8.7) … 3 (1.3) 3 (6.5) 8 (2.5)
Inflammatory bowel disease … … 6 (2.6) 1 (2.2) 7 (2.2)
PCR, Polymerase chain reaction.
∗ Data are presented as number (%) or as median (interquartile range).
† Two patients were COVID-19 antibody positive but polymerase PCR negative.
‡ One patient in this group had close contact with a COVID-19 laboratory positive patient.
§ Defined as sex assigned at birth.
‖ Calculated using state monthly averages in the United States and country monthly averages for the other countries listed.
Laboratory testing confirmed 23 patients (7%) were COVID-19 positive, including 13 by polymerase chain reaction (PCR) alone, 5 by antibody testing alone, 1 by combined PCR and antibody testing, and 4 by unknown assay. Of the 5 patients confirmed by antibody testing alone, 2 were immunoglobulin (Ig)M positive and IgG negative, with other patients' antibodies not specified. The 2 IgM-positive and IgG-negative antibody-confirmed patients both tested negative by PCR. PCR testing was not available for the other 3 antibody-positive patients. In addition, 20 patients had close contact with patients with confirmed COVID-19 (eg, child of health care worker who tested positive); though in 1 case, the patient subsequently tested PCR negative for COVID-19. Most cases (72%) were in patients with suspected COVID-19 without confirmatory testing at a time with limited testing access due to current testing criteria. These cases represent novel cases of new-onset pernio in patients without prior history, temporally associated with high levels of undetected community-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulation during the COVID-19 pandemic. Some patients who did receive testing had negative results: of 318 patients with pernio-like lesions, 46 were PCR negative and 14 were antibody negative.
Other COVID-19 symptoms were present in 45% of patients with pernio-like lesions. The most common were cough (21%), headache (15%), sore throat (12%), and fever (12%). When symptoms were present, the pernio-like lesions occurred before (13%), at the same time (15%), or after (54%) the COVID-19 symptoms. Patients generally had mild COVID-19 clinical courses, with 6 patients hospitalized, 2 of whom died. Of the 4 surviving hospitalized patients, 2 had uncomplicated courses, 1 patient required supplemental oxygen, and 1 required invasive mechanical ventilation. For 42 patients with the full course of pernio observed by providers, the lesions lasted for a median of 14 days (interquartile range, 10-21 days).
Pernio-like lesions affected only the feet in 84% of patients, only the hands in 5.1%, and a combination of the hands and feet in 10% (Fig 1 ). Associated acrocyanosis was seen in 9.2% and acral desquamation in 4.4%. Notably, 29% of patients lived in geographic regions with average March 2020 temperatures above 10°C, temperatures at which idiopathic pernio is less likely.
Fig 1 Pernio-like lesions on the (A-F) toes and (G) fingers in (A, C, D, E) COVID-19 polymerase chain reaction-positive patients, (E, F) antibody-positive patients, and (B, G) close contacts of COVID-19 polymerase chain reaction-positive patients.
Dermatopathology was available for 1 PCR-positive patient, demonstrating mild vacuolar interface dermatitis with dense superficial and deep lymphocytic inflammation, consistent with pernio vs connective tissue disease. No thrombi were noted. Six other pathology reports from patients without laboratory confirmation showed findings consistent with pernio-like changes: (1) 1 with mild spongiosis, vacuolar interface change, few apoptotic epidermal keratinocytes, and perivascular and perieccrine lymphoid infiltrate, (2) 3 reporting superficial and deep perivascular, perieccrine lymphocytic or lymphohistiocytic infiltrate, without evidence of vasculitis, (3) 1 reporting a subepidermal blister with small vessel lymphocytic vasculitis without microthrombi, and (4) 1 reporting lymphocytic vasculitis with rare microthrombi and overlying epidermal necrosis.
Discussion
Our registry-based, international collaborative series of patients presents the largest and most comprehensive collection of cases reported of pernio-like lesions as a cutaneous manifestation of confirmed or suspected COVID-19. Based on these data, we propose that this finding should prompt evaluation for the active or convalescent phase of infection. Patients in this case series were generally young, with few comorbidities, and had benign clinical courses. The pernio-like lesions in most patients developed either concurrently with, or after, COVID-19 symptoms, although 174 patients with confirmed or suspected COVID-19 presented only with pernio-like skin lesions. Given these findings, at a time when there continues to be significant undetected community-based SARS-CoV-2 transmission, we propose that pernio-like lesions should be considered in testing criteria for COVID-19, with larger population-based epidemiologic studies needed to confirm or refute this association.
Given evolving understanding of COVID-19, clear public health messaging regarding these pernio-like lesions is paramount. A key implication of COVID-19 cutaneous manifestations is the opportunity to recognize patients, especially asymptomatic ones, who are at risk for spreading infection. The fact that many of our patients were otherwise asymptomatic and had not been tested for COVID-19 likely reflects limited availability of COVID-19 PCR testing at the start of the United States outbreak and variable state-by-state and country-by-country testing regulations. In many locations, testing has been limited to sicker patients, selecting against testing of patients with mild disease, including those who may develop COVID-19–associated pernio-like skin lesions.
Also important is our ability to reassure the public regarding the relatively benign clinical course observed in most of our patients. Lesions in this series resolved in a median of 2 weeks. This duration is likely an underestimate, because the clinical courses of many patients are ongoing, and the data were only available for patients with completed disease courses.
Questions remain about patients who presented with pernio-like changes and presumed COVID-19 who were ultimately PCR negative. Explanations for these patients include (1) findings were not COVID-19-related, (2) false-negative test results, or (3) testing occurred after viral clearance, with pernio-like lesions representing a late clinical finding. Although multiple possibilities exist, reports from Europe of pernio-like lesions during the COVID-19 surge suggest a true association,1 , 4 , 5 with pernio-like findings most commonly appearing in younger patients and later in the disease course.1
New developments in COVID-19 antibody testing may further clarify the timing of pernio-like lesions in the COVID-19 clinical course. Of the 20 patients known to have antibody testing (IgM, IgG, unspecified, or both), only 6 (30%) tested positive. Two of these patients were PCR negative but IgM positive. Early studies have suggested that for antibody response to SARS-CoV-2, IgM peaks at day 28 whereas IgG peaks at day 49 after the onset of illness.7 Although there is a possibility that IgM positivity represents a false positive, if reliable, it instead supports the theory that antibody testing would be an important part of the evaluation of pernio-like lesions to rule out COVID-19. Further, if pernio is indeed a later disease course phenomenon in at least a subset of patients, then it may be prudent to repeat antibody testing and/or seek delayed IgG testing for suspected patients.
We must critically examine with further investigation why some patients with COVID-19–associated pernio-like lesions might test negative with current antibody testing. Immunocompromised patients may fail to generate antibodies, but most patients with COVID-19–associated pernio-like lesions are otherwise healthy young patients whose skin lesions developed late in their course with theoretically sufficient time to generate IgM or IgG antibodies, or both.
There are several possible explanations. Certainly, some patients may have new-onset pernio from other non–COVID-19 causes. That may be true for some of these patients, but given the large number of new reports of pernio coincidentally with the COVID-19 pandemic, it is unlikely to explain all cases. Some patients in the registry with negative antibodies had clinical histories predictive of high pretest probability; for example, a physician caring for COVID-19 patients in Milan and a child with a PCR-positive parent. One possibility is false-negative test results, because there is significant variability in the sensitivity and specificity of current tests on the market.8 , 9 It is also possible that many patients with COVID-19 may have a delayed antibody responses. Another, more worrisome, explanation is that the antibody response in patients with relatively mild disease tends not to be as brisk.7 , 10 This explanation is concerning, because it would both question the validity of our current antibody testing and suggest that patients with mild or asymptomatic disease may not generate antibodies (and possible immunity) upon infection with SARS-Cov-2. Finally, reliable testing combined with coordination of timing of these skin changes with COVID-19 PCR, IgG, and IgM testing results is imperative to better establish self-isolation recommendations for patients presenting with pernio-like lesions.
There are multiple potential pathophysiologic mechanisms underpinning pernio-like lesions in COVID-19. In nonepidemic settings, pernio is often idiopathic or related to underlying disease (eg, systemic lupus erythematosus or antiphospholipid antibody syndrome), and cannot easily be ascertained with histopathology alone.11 The histopathology reported for 1 of the COVID-19 PCR-positive patients, as well as 4 of 6 patients with suspected COVID-19, demonstrated features consistent with pernio without evidence of vascular damage, suggesting COVID-19–associated pernio-like lesions may be simply inflammatory. The other 2 of 6 patients with suspected COVID-19 with histopathology reported vascular changes, including lymphocytic vasculitis, which can sometimes be seen in conjunction with variants of pernio. Indeed, interferon response to viral infection appears to be a clue why some patients do poorly while others fare well.12 , 13
Less likely, but worthy of consideration, is that prothrombotic coagulopathy may be a contributing factor, as suggested by COVID-19 cases complicated by venous thromboembolism, pathologic reports of microvascular thrombosis,14 and laboratory abnormalities including elevated D-dimer and high fibrinogen.15, 16, 17 Furthermore, antiphospholipid antibodies have been implicated in a small case series of patients acutely ill with COVID-1918 and have previously been associated with pernio. With greater clinical and pathologic correlation, we hope to better understand the pathophysiology, including understanding how, if at all, hypercoagulability plays a role in COVID-19–associated pernio-like lesions. Importantly, although young patients with COVID-19 have presented with stroke, we are not aware of any cases of concomitant pernio-like lesions and strokes.19
Limitations of this case series include incomplete testing for COVID-19, especially in otherwise asymptomatic patients. We are also unable to estimate the incidence or prevalence of this condition. There may be confirmation bias in reporting of cases. In addition, the background incidence of pernio from other causes in March and April is not well documented.6 We cannot exclude an epiphenomenon, because this case series cannot establish causation. Future studies are needed to assess the histopathology of pernio-like lesions to inform understanding of the disease process.
Conclusion
Our case series demonstrates pernio-like skin lesions as a manifestation of COVID-19. Patients with pernio-like lesions of COVID-19 may still be infectious and pose a public health risk, because skin lesions developed in at least 4 patients in this report before COVID-19 PCR confirmation, and the lesions developed in 14 while still PCR positive. We propose that pernio-like lesions be added to the testing criteria for COVID-19 and prompt consideration of testing for both PCR and IgM and IgG antibodies. This information will be critical to understanding the significance of these cutaneous lesions and empowering physicians and other health care providers to counsel patients appropriately.
|
|
p
|
Capsule Summary
• This large international registry-based case series adds to the emerging evidence that pernio-like lesions may be a cutaneous manifestation of COVID-19.
• Patients with pernio-like lesions generally had benign clinical courses. Importantly, because some of these patients may be infectious, isolation and COVID-19 testing must be considered.
|
|
caption
|
Capsule Summary
|
|
title
|
Capsule Summary
|
|
p
|
• This large international registry-based case series adds to the emerging evidence that pernio-like lesions may be a cutaneous manifestation of COVID-19.
• Patients with pernio-like lesions generally had benign clinical courses. Importantly, because some of these patients may be infectious, isolation and COVID-19 testing must be considered.
|
|
label
|
•
|
|
p
|
This large international registry-based case series adds to the emerging evidence that pernio-like lesions may be a cutaneous manifestation of COVID-19.
|
|
label
|
•
|
|
p
|
Patients with pernio-like lesions generally had benign clinical courses. Importantly, because some of these patients may be infectious, isolation and COVID-19 testing must be considered.
|
|
p
|
Emerging evidence suggests that coronavirus infectious disease 2019 (COVID-19) has associated dermatologic manifestations. Many cutaneous findings of COVID-19 are nonspecific, such as morbilliform exanthems, urticarial eruptions, and vesicular lesions, and are often seen in the context of other viral infections.1, 2, 3 In contrast, recent reports from around the globe highlight a striking pernio-like phenomenon in association with COVID-19.1 , 4 , 5 Pernio, or chilblains, is a superficial inflammatory vascular response that occurs on acral skin, usually after cold exposure, typically in children and young to middle-aged women.6 In this large international registry-based case series, we evaluate clinical characteristics of patients with suspected or confirmed COVID-19 who presented with pernio-like lesions on acral surfaces. Our objectives were to assess location, timing, and duration of the pernio-like lesions, and to analyze patients' comorbidities, COVID-19 severity, and disease outcomes.
|
|
sec
|
Methods
We established a registry to collect cases of COVID-19 with dermatologic manifestations reported by medical professionals, with data collected from April 8, 2020, to May 2, 2020. The registry was widely promoted to members of the American Academy of Dermatology, major dermatology subspecialty groups, the International League of Dermatologic Societies, and dermatology and general medicine groups on social media. The website (www.aad.org/covidregistry) was hosted through a Massachusetts General Hospital REDCap (Research Electronic Data Capture, Vanderbilt University, Nashville, TN) database. The registry queried patient demographics, dermatologic symptoms, COVID-19 history and symptoms, and past medical history. For this subanalysis, we included patients with new-onset pernio-like skin changes in the setting of confirmed or suspected COVID-19 and excluded patients with prior history of pernio. The deidentified patient data was analyzed using Stata 16 software (StataCorp, College Station, TX). The registry was reviewed by Partners Healthcare Institutional Review Board and was determined to not meet the definition of Human Subjects Research.
|
|
title
|
Methods
|
|
p
|
We established a registry to collect cases of COVID-19 with dermatologic manifestations reported by medical professionals, with data collected from April 8, 2020, to May 2, 2020. The registry was widely promoted to members of the American Academy of Dermatology, major dermatology subspecialty groups, the International League of Dermatologic Societies, and dermatology and general medicine groups on social media. The website (www.aad.org/covidregistry) was hosted through a Massachusetts General Hospital REDCap (Research Electronic Data Capture, Vanderbilt University, Nashville, TN) database. The registry queried patient demographics, dermatologic symptoms, COVID-19 history and symptoms, and past medical history. For this subanalysis, we included patients with new-onset pernio-like skin changes in the setting of confirmed or suspected COVID-19 and excluded patients with prior history of pernio. The deidentified patient data was analyzed using Stata 16 software (StataCorp, College Station, TX). The registry was reviewed by Partners Healthcare Institutional Review Board and was determined to not meet the definition of Human Subjects Research.
|
|
sec
|
Results
The registry compiled 505 cases of dermatologic manifestations associated with COVID-19 over 25 days, reported by dermatologists (50%), other physicians (37%), and midlevel practitioners (8%). There were 318 patients (63%) identified with pernio-like changes in the setting of confirmed or suspected COVID-19 (Table I ). Patients were generally young and healthy, with median age of 25 years (interquartile range, 17-38 years), including 93 children and adolescents. Only 25% had medical comorbidities.
Table I Clinical characteristics of patients with confirmed and suspected COVID-19 who developed pernio-like lesions on acral skin
Characteristic∗ COVID-19 laboratory positive (n = 23)† Close contact with COVID-19 laboratory positive (n = 20) COVID-19 clinical suspicion (n = 229) COVID-19 PCR negative‡ (n = 46) Overall (n = 318)
Age, years 41 (23-57) 24 (17-37) 24 (17-37) 27 (16-36) 25 (17-38)
Female sex§ 11 (48) 5 (25) 118 (52) 21 (46) 155 (49)
Race/ethnicity‖
White 18 (86) 17 (94) 195 (91) 38 (83) 268 (89)
Asian 1 (4.8) 1 (5.6) 14 (6.5) 6 (13) 22 (7.3)
Black/African American 0 (0.0) 0 (0.0) 1 (0.5) 1 (2.2) 2 (0.7)
Hispanic/Latino 2 (9.5) 0 (0.0) 5 (2.3) 1 (2.2) 8 (2.7)
Country of residence
United States 22 (96) 17 (85) 212 (93) 42 (91) 293 (92)
Canada 0 (0.0) 1 (5.0) 6 (2.6) 4 (8.7) 11 (3.5)
France 0 (0.0) 1 (5.0) 4 (1.8) 0 (0.0) 5 (1.6)
United Kingdom 1 (4.3) 1 (5.0) 2 (0.9) 0 (0.0) 4 (1.3)
Italy 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Mexico 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Netherlands 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Iran 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Average monthly temperature‖
Above 10°C 4 (18) 1 (5.0) 66 (29) 20 (43) 91 (29)
Below 10°C 19 (82) 19 (95) 163 (71) 26 (57) 227 (71)
Body site affected
Foot 20 (87) 19 (95) 216 (94) 43 (93) 298 (94)
Hand 7 (30) 2 (10) 31 (14) 8 (17) 48 (15)
Dermatologic symptoms
Asymptomatic 4 (17) 2 (10) 24 (11) 6 (13) 36 (11)
Pain/burning 16 (70) 16 (80) 144 (63) 35 (76) 211 (66)
Pruritus 8 (35) 9 (45) 99 (43) 21 (46) 137 (43)
Cold intolerance 2 (8.7) 2 (10) 17 (7.4) 1 (2.2) 22 (6.9)
Timing of dermatologic changes
Before COVID-19 symptoms 4 (17) 0 (0.0) 12 (5.4) 3 (6.5) 19 (6.1)
After COVID-19 symptoms 11 (48) 6 (30) 48 (22) 15 (33) 80 (26)
At the same time as COVID-19 3 (13) 1 (5.0) 14 (6.3) 4 (8.7) 22 (7.1)
No other COVID-19 symptoms 5 (22) 12 (60) 132 (59) 21 (46) 170 (55)
Unknown 0 (0.0) 1 (5.0) 17 (7.6) 3 (6.5) 21 (6.7)
COVID-19 exposure
None (community acquired) 7 (30) 0 (0.0) 126 (55) 20 (43) 153 (48)
Close contact with patient with
Confirmed COVID-19 3 (13) 20 (100) 0 (0.0) 1 (2.1) 24 (7.5)
Suspected COVID-19 8 (35) 4 (20) 26 (11) 6 (13) 44 (14)
Presence in a health care facility where COVID-19 infections have been managed 1 (4.3) 0 (0.0) 10 (4.4) 7 (15) 18 (5.7)
COVID-19 symptoms
Asymptomatic 5 (22) 10 (50) 140 (61) 19 (41) 174 (55)
Cough 9 (39) 3 (15) 41 (18) 14 (30) 67 (21)
Headache 7 (30) 4 (20) 27 (12) 9 (20) 47 (15)
Sore throat 5 (22) 4 (20) 21 (9.2) 8 (17) 38 (12)
Fever 9 (39) 1 (5.0) 18 (7.9) 9 (20) 37 (12)
Malaise 4 (17) 1 (5.0) 20 (8.7) 6 (13) 31 (9.7)
Shortness of breath 6 (26) 1 (5.0) 16 (7.0) 6 (13) 29 (9.1)
COVID-19 level of care
Outpatient care only 18 (78) 20 (100) 229 (100) 45 (98) 312 (98)
Hospitalized, alive 3 (13) … … 1 (2.2) 4 (1.3)
Hospitalized, died 2 (8.7) … … … 2 (0.6)
Comorbid medical conditions
None 17 (74) 12 (60) 172 (75) 36 (78) 237 (75)
Obstructive lung disease 2 (8.7) 2 (10) 12 (5.2) 1 (2.2) 17 (5.3)
Hypertension 2 (8.7) 1 (5.0) 5 (2.2) 1 (2.2) 9 (2.8)
Rheumatologic disease 2 (8.7) … 3 (1.3) 3 (6.5) 8 (2.5)
Inflammatory bowel disease … … 6 (2.6) 1 (2.2) 7 (2.2)
PCR, Polymerase chain reaction.
∗ Data are presented as number (%) or as median (interquartile range).
† Two patients were COVID-19 antibody positive but polymerase PCR negative.
‡ One patient in this group had close contact with a COVID-19 laboratory positive patient.
§ Defined as sex assigned at birth.
‖ Calculated using state monthly averages in the United States and country monthly averages for the other countries listed.
Laboratory testing confirmed 23 patients (7%) were COVID-19 positive, including 13 by polymerase chain reaction (PCR) alone, 5 by antibody testing alone, 1 by combined PCR and antibody testing, and 4 by unknown assay. Of the 5 patients confirmed by antibody testing alone, 2 were immunoglobulin (Ig)M positive and IgG negative, with other patients' antibodies not specified. The 2 IgM-positive and IgG-negative antibody-confirmed patients both tested negative by PCR. PCR testing was not available for the other 3 antibody-positive patients. In addition, 20 patients had close contact with patients with confirmed COVID-19 (eg, child of health care worker who tested positive); though in 1 case, the patient subsequently tested PCR negative for COVID-19. Most cases (72%) were in patients with suspected COVID-19 without confirmatory testing at a time with limited testing access due to current testing criteria. These cases represent novel cases of new-onset pernio in patients without prior history, temporally associated with high levels of undetected community-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulation during the COVID-19 pandemic. Some patients who did receive testing had negative results: of 318 patients with pernio-like lesions, 46 were PCR negative and 14 were antibody negative.
Other COVID-19 symptoms were present in 45% of patients with pernio-like lesions. The most common were cough (21%), headache (15%), sore throat (12%), and fever (12%). When symptoms were present, the pernio-like lesions occurred before (13%), at the same time (15%), or after (54%) the COVID-19 symptoms. Patients generally had mild COVID-19 clinical courses, with 6 patients hospitalized, 2 of whom died. Of the 4 surviving hospitalized patients, 2 had uncomplicated courses, 1 patient required supplemental oxygen, and 1 required invasive mechanical ventilation. For 42 patients with the full course of pernio observed by providers, the lesions lasted for a median of 14 days (interquartile range, 10-21 days).
Pernio-like lesions affected only the feet in 84% of patients, only the hands in 5.1%, and a combination of the hands and feet in 10% (Fig 1 ). Associated acrocyanosis was seen in 9.2% and acral desquamation in 4.4%. Notably, 29% of patients lived in geographic regions with average March 2020 temperatures above 10°C, temperatures at which idiopathic pernio is less likely.
Fig 1 Pernio-like lesions on the (A-F) toes and (G) fingers in (A, C, D, E) COVID-19 polymerase chain reaction-positive patients, (E, F) antibody-positive patients, and (B, G) close contacts of COVID-19 polymerase chain reaction-positive patients.
Dermatopathology was available for 1 PCR-positive patient, demonstrating mild vacuolar interface dermatitis with dense superficial and deep lymphocytic inflammation, consistent with pernio vs connective tissue disease. No thrombi were noted. Six other pathology reports from patients without laboratory confirmation showed findings consistent with pernio-like changes: (1) 1 with mild spongiosis, vacuolar interface change, few apoptotic epidermal keratinocytes, and perivascular and perieccrine lymphoid infiltrate, (2) 3 reporting superficial and deep perivascular, perieccrine lymphocytic or lymphohistiocytic infiltrate, without evidence of vasculitis, (3) 1 reporting a subepidermal blister with small vessel lymphocytic vasculitis without microthrombi, and (4) 1 reporting lymphocytic vasculitis with rare microthrombi and overlying epidermal necrosis.
|
|
title
|
Results
|
|
p
|
The registry compiled 505 cases of dermatologic manifestations associated with COVID-19 over 25 days, reported by dermatologists (50%), other physicians (37%), and midlevel practitioners (8%). There were 318 patients (63%) identified with pernio-like changes in the setting of confirmed or suspected COVID-19 (Table I ). Patients were generally young and healthy, with median age of 25 years (interquartile range, 17-38 years), including 93 children and adolescents. Only 25% had medical comorbidities.
Table I Clinical characteristics of patients with confirmed and suspected COVID-19 who developed pernio-like lesions on acral skin
Characteristic∗ COVID-19 laboratory positive (n = 23)† Close contact with COVID-19 laboratory positive (n = 20) COVID-19 clinical suspicion (n = 229) COVID-19 PCR negative‡ (n = 46) Overall (n = 318)
Age, years 41 (23-57) 24 (17-37) 24 (17-37) 27 (16-36) 25 (17-38)
Female sex§ 11 (48) 5 (25) 118 (52) 21 (46) 155 (49)
Race/ethnicity‖
White 18 (86) 17 (94) 195 (91) 38 (83) 268 (89)
Asian 1 (4.8) 1 (5.6) 14 (6.5) 6 (13) 22 (7.3)
Black/African American 0 (0.0) 0 (0.0) 1 (0.5) 1 (2.2) 2 (0.7)
Hispanic/Latino 2 (9.5) 0 (0.0) 5 (2.3) 1 (2.2) 8 (2.7)
Country of residence
United States 22 (96) 17 (85) 212 (93) 42 (91) 293 (92)
Canada 0 (0.0) 1 (5.0) 6 (2.6) 4 (8.7) 11 (3.5)
France 0 (0.0) 1 (5.0) 4 (1.8) 0 (0.0) 5 (1.6)
United Kingdom 1 (4.3) 1 (5.0) 2 (0.9) 0 (0.0) 4 (1.3)
Italy 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Mexico 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Netherlands 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Iran 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Average monthly temperature‖
Above 10°C 4 (18) 1 (5.0) 66 (29) 20 (43) 91 (29)
Below 10°C 19 (82) 19 (95) 163 (71) 26 (57) 227 (71)
Body site affected
Foot 20 (87) 19 (95) 216 (94) 43 (93) 298 (94)
Hand 7 (30) 2 (10) 31 (14) 8 (17) 48 (15)
Dermatologic symptoms
Asymptomatic 4 (17) 2 (10) 24 (11) 6 (13) 36 (11)
Pain/burning 16 (70) 16 (80) 144 (63) 35 (76) 211 (66)
Pruritus 8 (35) 9 (45) 99 (43) 21 (46) 137 (43)
Cold intolerance 2 (8.7) 2 (10) 17 (7.4) 1 (2.2) 22 (6.9)
Timing of dermatologic changes
Before COVID-19 symptoms 4 (17) 0 (0.0) 12 (5.4) 3 (6.5) 19 (6.1)
After COVID-19 symptoms 11 (48) 6 (30) 48 (22) 15 (33) 80 (26)
At the same time as COVID-19 3 (13) 1 (5.0) 14 (6.3) 4 (8.7) 22 (7.1)
No other COVID-19 symptoms 5 (22) 12 (60) 132 (59) 21 (46) 170 (55)
Unknown 0 (0.0) 1 (5.0) 17 (7.6) 3 (6.5) 21 (6.7)
COVID-19 exposure
None (community acquired) 7 (30) 0 (0.0) 126 (55) 20 (43) 153 (48)
Close contact with patient with
Confirmed COVID-19 3 (13) 20 (100) 0 (0.0) 1 (2.1) 24 (7.5)
Suspected COVID-19 8 (35) 4 (20) 26 (11) 6 (13) 44 (14)
Presence in a health care facility where COVID-19 infections have been managed 1 (4.3) 0 (0.0) 10 (4.4) 7 (15) 18 (5.7)
COVID-19 symptoms
Asymptomatic 5 (22) 10 (50) 140 (61) 19 (41) 174 (55)
Cough 9 (39) 3 (15) 41 (18) 14 (30) 67 (21)
Headache 7 (30) 4 (20) 27 (12) 9 (20) 47 (15)
Sore throat 5 (22) 4 (20) 21 (9.2) 8 (17) 38 (12)
Fever 9 (39) 1 (5.0) 18 (7.9) 9 (20) 37 (12)
Malaise 4 (17) 1 (5.0) 20 (8.7) 6 (13) 31 (9.7)
Shortness of breath 6 (26) 1 (5.0) 16 (7.0) 6 (13) 29 (9.1)
COVID-19 level of care
Outpatient care only 18 (78) 20 (100) 229 (100) 45 (98) 312 (98)
Hospitalized, alive 3 (13) … … 1 (2.2) 4 (1.3)
Hospitalized, died 2 (8.7) … … … 2 (0.6)
Comorbid medical conditions
None 17 (74) 12 (60) 172 (75) 36 (78) 237 (75)
Obstructive lung disease 2 (8.7) 2 (10) 12 (5.2) 1 (2.2) 17 (5.3)
Hypertension 2 (8.7) 1 (5.0) 5 (2.2) 1 (2.2) 9 (2.8)
Rheumatologic disease 2 (8.7) … 3 (1.3) 3 (6.5) 8 (2.5)
Inflammatory bowel disease … … 6 (2.6) 1 (2.2) 7 (2.2)
PCR, Polymerase chain reaction.
∗ Data are presented as number (%) or as median (interquartile range).
† Two patients were COVID-19 antibody positive but polymerase PCR negative.
‡ One patient in this group had close contact with a COVID-19 laboratory positive patient.
§ Defined as sex assigned at birth.
‖ Calculated using state monthly averages in the United States and country monthly averages for the other countries listed.
|
|
table-wrap
|
Table I Clinical characteristics of patients with confirmed and suspected COVID-19 who developed pernio-like lesions on acral skin
Characteristic∗ COVID-19 laboratory positive (n = 23)† Close contact with COVID-19 laboratory positive (n = 20) COVID-19 clinical suspicion (n = 229) COVID-19 PCR negative‡ (n = 46) Overall (n = 318)
Age, years 41 (23-57) 24 (17-37) 24 (17-37) 27 (16-36) 25 (17-38)
Female sex§ 11 (48) 5 (25) 118 (52) 21 (46) 155 (49)
Race/ethnicity‖
White 18 (86) 17 (94) 195 (91) 38 (83) 268 (89)
Asian 1 (4.8) 1 (5.6) 14 (6.5) 6 (13) 22 (7.3)
Black/African American 0 (0.0) 0 (0.0) 1 (0.5) 1 (2.2) 2 (0.7)
Hispanic/Latino 2 (9.5) 0 (0.0) 5 (2.3) 1 (2.2) 8 (2.7)
Country of residence
United States 22 (96) 17 (85) 212 (93) 42 (91) 293 (92)
Canada 0 (0.0) 1 (5.0) 6 (2.6) 4 (8.7) 11 (3.5)
France 0 (0.0) 1 (5.0) 4 (1.8) 0 (0.0) 5 (1.6)
United Kingdom 1 (4.3) 1 (5.0) 2 (0.9) 0 (0.0) 4 (1.3)
Italy 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Mexico 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Netherlands 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Iran 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Average monthly temperature‖
Above 10°C 4 (18) 1 (5.0) 66 (29) 20 (43) 91 (29)
Below 10°C 19 (82) 19 (95) 163 (71) 26 (57) 227 (71)
Body site affected
Foot 20 (87) 19 (95) 216 (94) 43 (93) 298 (94)
Hand 7 (30) 2 (10) 31 (14) 8 (17) 48 (15)
Dermatologic symptoms
Asymptomatic 4 (17) 2 (10) 24 (11) 6 (13) 36 (11)
Pain/burning 16 (70) 16 (80) 144 (63) 35 (76) 211 (66)
Pruritus 8 (35) 9 (45) 99 (43) 21 (46) 137 (43)
Cold intolerance 2 (8.7) 2 (10) 17 (7.4) 1 (2.2) 22 (6.9)
Timing of dermatologic changes
Before COVID-19 symptoms 4 (17) 0 (0.0) 12 (5.4) 3 (6.5) 19 (6.1)
After COVID-19 symptoms 11 (48) 6 (30) 48 (22) 15 (33) 80 (26)
At the same time as COVID-19 3 (13) 1 (5.0) 14 (6.3) 4 (8.7) 22 (7.1)
No other COVID-19 symptoms 5 (22) 12 (60) 132 (59) 21 (46) 170 (55)
Unknown 0 (0.0) 1 (5.0) 17 (7.6) 3 (6.5) 21 (6.7)
COVID-19 exposure
None (community acquired) 7 (30) 0 (0.0) 126 (55) 20 (43) 153 (48)
Close contact with patient with
Confirmed COVID-19 3 (13) 20 (100) 0 (0.0) 1 (2.1) 24 (7.5)
Suspected COVID-19 8 (35) 4 (20) 26 (11) 6 (13) 44 (14)
Presence in a health care facility where COVID-19 infections have been managed 1 (4.3) 0 (0.0) 10 (4.4) 7 (15) 18 (5.7)
COVID-19 symptoms
Asymptomatic 5 (22) 10 (50) 140 (61) 19 (41) 174 (55)
Cough 9 (39) 3 (15) 41 (18) 14 (30) 67 (21)
Headache 7 (30) 4 (20) 27 (12) 9 (20) 47 (15)
Sore throat 5 (22) 4 (20) 21 (9.2) 8 (17) 38 (12)
Fever 9 (39) 1 (5.0) 18 (7.9) 9 (20) 37 (12)
Malaise 4 (17) 1 (5.0) 20 (8.7) 6 (13) 31 (9.7)
Shortness of breath 6 (26) 1 (5.0) 16 (7.0) 6 (13) 29 (9.1)
COVID-19 level of care
Outpatient care only 18 (78) 20 (100) 229 (100) 45 (98) 312 (98)
Hospitalized, alive 3 (13) … … 1 (2.2) 4 (1.3)
Hospitalized, died 2 (8.7) … … … 2 (0.6)
Comorbid medical conditions
None 17 (74) 12 (60) 172 (75) 36 (78) 237 (75)
Obstructive lung disease 2 (8.7) 2 (10) 12 (5.2) 1 (2.2) 17 (5.3)
Hypertension 2 (8.7) 1 (5.0) 5 (2.2) 1 (2.2) 9 (2.8)
Rheumatologic disease 2 (8.7) … 3 (1.3) 3 (6.5) 8 (2.5)
Inflammatory bowel disease … … 6 (2.6) 1 (2.2) 7 (2.2)
PCR, Polymerase chain reaction.
∗ Data are presented as number (%) or as median (interquartile range).
† Two patients were COVID-19 antibody positive but polymerase PCR negative.
‡ One patient in this group had close contact with a COVID-19 laboratory positive patient.
§ Defined as sex assigned at birth.
‖ Calculated using state monthly averages in the United States and country monthly averages for the other countries listed.
|
|
label
|
Table I
|
|
caption
|
Clinical characteristics of patients with confirmed and suspected COVID-19 who developed pernio-like lesions on acral skin
|
|
p
|
Clinical characteristics of patients with confirmed and suspected COVID-19 who developed pernio-like lesions on acral skin
|
|
table
|
Characteristic∗ COVID-19 laboratory positive (n = 23)† Close contact with COVID-19 laboratory positive (n = 20) COVID-19 clinical suspicion (n = 229) COVID-19 PCR negative‡ (n = 46) Overall (n = 318)
Age, years 41 (23-57) 24 (17-37) 24 (17-37) 27 (16-36) 25 (17-38)
Female sex§ 11 (48) 5 (25) 118 (52) 21 (46) 155 (49)
Race/ethnicity‖
White 18 (86) 17 (94) 195 (91) 38 (83) 268 (89)
Asian 1 (4.8) 1 (5.6) 14 (6.5) 6 (13) 22 (7.3)
Black/African American 0 (0.0) 0 (0.0) 1 (0.5) 1 (2.2) 2 (0.7)
Hispanic/Latino 2 (9.5) 0 (0.0) 5 (2.3) 1 (2.2) 8 (2.7)
Country of residence
United States 22 (96) 17 (85) 212 (93) 42 (91) 293 (92)
Canada 0 (0.0) 1 (5.0) 6 (2.6) 4 (8.7) 11 (3.5)
France 0 (0.0) 1 (5.0) 4 (1.8) 0 (0.0) 5 (1.6)
United Kingdom 1 (4.3) 1 (5.0) 2 (0.9) 0 (0.0) 4 (1.3)
Italy 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Mexico 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Netherlands 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Iran 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
Average monthly temperature‖
Above 10°C 4 (18) 1 (5.0) 66 (29) 20 (43) 91 (29)
Below 10°C 19 (82) 19 (95) 163 (71) 26 (57) 227 (71)
Body site affected
Foot 20 (87) 19 (95) 216 (94) 43 (93) 298 (94)
Hand 7 (30) 2 (10) 31 (14) 8 (17) 48 (15)
Dermatologic symptoms
Asymptomatic 4 (17) 2 (10) 24 (11) 6 (13) 36 (11)
Pain/burning 16 (70) 16 (80) 144 (63) 35 (76) 211 (66)
Pruritus 8 (35) 9 (45) 99 (43) 21 (46) 137 (43)
Cold intolerance 2 (8.7) 2 (10) 17 (7.4) 1 (2.2) 22 (6.9)
Timing of dermatologic changes
Before COVID-19 symptoms 4 (17) 0 (0.0) 12 (5.4) 3 (6.5) 19 (6.1)
After COVID-19 symptoms 11 (48) 6 (30) 48 (22) 15 (33) 80 (26)
At the same time as COVID-19 3 (13) 1 (5.0) 14 (6.3) 4 (8.7) 22 (7.1)
No other COVID-19 symptoms 5 (22) 12 (60) 132 (59) 21 (46) 170 (55)
Unknown 0 (0.0) 1 (5.0) 17 (7.6) 3 (6.5) 21 (6.7)
COVID-19 exposure
None (community acquired) 7 (30) 0 (0.0) 126 (55) 20 (43) 153 (48)
Close contact with patient with
Confirmed COVID-19 3 (13) 20 (100) 0 (0.0) 1 (2.1) 24 (7.5)
Suspected COVID-19 8 (35) 4 (20) 26 (11) 6 (13) 44 (14)
Presence in a health care facility where COVID-19 infections have been managed 1 (4.3) 0 (0.0) 10 (4.4) 7 (15) 18 (5.7)
COVID-19 symptoms
Asymptomatic 5 (22) 10 (50) 140 (61) 19 (41) 174 (55)
Cough 9 (39) 3 (15) 41 (18) 14 (30) 67 (21)
Headache 7 (30) 4 (20) 27 (12) 9 (20) 47 (15)
Sore throat 5 (22) 4 (20) 21 (9.2) 8 (17) 38 (12)
Fever 9 (39) 1 (5.0) 18 (7.9) 9 (20) 37 (12)
Malaise 4 (17) 1 (5.0) 20 (8.7) 6 (13) 31 (9.7)
Shortness of breath 6 (26) 1 (5.0) 16 (7.0) 6 (13) 29 (9.1)
COVID-19 level of care
Outpatient care only 18 (78) 20 (100) 229 (100) 45 (98) 312 (98)
Hospitalized, alive 3 (13) … … 1 (2.2) 4 (1.3)
Hospitalized, died 2 (8.7) … … … 2 (0.6)
Comorbid medical conditions
None 17 (74) 12 (60) 172 (75) 36 (78) 237 (75)
Obstructive lung disease 2 (8.7) 2 (10) 12 (5.2) 1 (2.2) 17 (5.3)
Hypertension 2 (8.7) 1 (5.0) 5 (2.2) 1 (2.2) 9 (2.8)
Rheumatologic disease 2 (8.7) … 3 (1.3) 3 (6.5) 8 (2.5)
Inflammatory bowel disease … … 6 (2.6) 1 (2.2) 7 (2.2)
|
|
tr
|
Characteristic∗ COVID-19 laboratory positive (n = 23)† Close contact with COVID-19 laboratory positive (n = 20) COVID-19 clinical suspicion (n = 229) COVID-19 PCR negative‡ (n = 46) Overall (n = 318)
|
|
th
|
Characteristic∗
|
|
th
|
COVID-19 laboratory positive (n = 23)†
|
|
th
|
Close contact with COVID-19 laboratory positive (n = 20)
|
|
th
|
COVID-19 clinical suspicion (n = 229)
|
|
th
|
COVID-19 PCR negative‡ (n = 46)
|
|
th
|
Overall (n = 318)
|
|
tr
|
Age, years 41 (23-57) 24 (17-37) 24 (17-37) 27 (16-36) 25 (17-38)
|
|
td
|
Age, years
|
|
td
|
41 (23-57)
|
|
td
|
24 (17-37)
|
|
td
|
24 (17-37)
|
|
td
|
27 (16-36)
|
|
td
|
25 (17-38)
|
|
tr
|
Female sex§ 11 (48) 5 (25) 118 (52) 21 (46) 155 (49)
|
|
td
|
Female sex§
|
|
td
|
11 (48)
|
|
td
|
5 (25)
|
|
td
|
118 (52)
|
|
td
|
21 (46)
|
|
td
|
155 (49)
|
|
tr
|
Race/ethnicity‖
|
|
td
|
Race/ethnicity‖
|
|
tr
|
White 18 (86) 17 (94) 195 (91) 38 (83) 268 (89)
|
|
td
|
White
|
|
td
|
18 (86)
|
|
td
|
17 (94)
|
|
td
|
195 (91)
|
|
td
|
38 (83)
|
|
td
|
268 (89)
|
|
tr
|
Asian 1 (4.8) 1 (5.6) 14 (6.5) 6 (13) 22 (7.3)
|
|
td
|
Asian
|
|
td
|
1 (4.8)
|
|
td
|
1 (5.6)
|
|
td
|
14 (6.5)
|
|
td
|
6 (13)
|
|
td
|
22 (7.3)
|
|
tr
|
Black/African American 0 (0.0) 0 (0.0) 1 (0.5) 1 (2.2) 2 (0.7)
|
|
td
|
Black/African American
|
|
td
|
0 (0.0)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.5)
|
|
td
|
1 (2.2)
|
|
td
|
2 (0.7)
|
|
tr
|
Hispanic/Latino 2 (9.5) 0 (0.0) 5 (2.3) 1 (2.2) 8 (2.7)
|
|
td
|
Hispanic/Latino
|
|
td
|
2 (9.5)
|
|
td
|
0 (0.0)
|
|
td
|
5 (2.3)
|
|
td
|
1 (2.2)
|
|
td
|
8 (2.7)
|
|
tr
|
Country of residence
|
|
td
|
Country of residence
|
|
tr
|
United States 22 (96) 17 (85) 212 (93) 42 (91) 293 (92)
|
|
td
|
United States
|
|
td
|
22 (96)
|
|
td
|
17 (85)
|
|
td
|
212 (93)
|
|
td
|
42 (91)
|
|
td
|
293 (92)
|
|
tr
|
Canada 0 (0.0) 1 (5.0) 6 (2.6) 4 (8.7) 11 (3.5)
|
|
td
|
Canada
|
|
td
|
0 (0.0)
|
|
td
|
1 (5.0)
|
|
td
|
6 (2.6)
|
|
td
|
4 (8.7)
|
|
td
|
11 (3.5)
|
|
tr
|
France 0 (0.0) 1 (5.0) 4 (1.8) 0 (0.0) 5 (1.6)
|
|
td
|
France
|
|
td
|
0 (0.0)
|
|
td
|
1 (5.0)
|
|
td
|
4 (1.8)
|
|
td
|
0 (0.0)
|
|
td
|
5 (1.6)
|
|
tr
|
United Kingdom 1 (4.3) 1 (5.0) 2 (0.9) 0 (0.0) 4 (1.3)
|
|
td
|
United Kingdom
|
|
td
|
1 (4.3)
|
|
td
|
1 (5.0)
|
|
td
|
2 (0.9)
|
|
td
|
0 (0.0)
|
|
td
|
4 (1.3)
|
|
tr
|
Italy 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
|
|
td
|
Italy
|
|
td
|
0 (0.0)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.4)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.3)
|
|
tr
|
Mexico 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
|
|
td
|
Mexico
|
|
td
|
0 (0.0)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.4)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.3)
|
|
tr
|
Netherlands 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
|
|
td
|
Netherlands
|
|
td
|
0 (0.0)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.4)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.3)
|
|
tr
|
Iran 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.3)
|
|
td
|
Iran
|
|
td
|
0 (0.0)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.4)
|
|
td
|
0 (0.0)
|
|
td
|
1 (0.3)
|
|
tr
|
Average monthly temperature‖
|
|
td
|
Average monthly temperature‖
|
|
tr
|
Above 10°C 4 (18) 1 (5.0) 66 (29) 20 (43) 91 (29)
|
|
td
|
Above 10°C
|
|
td
|
4 (18)
|
|
td
|
1 (5.0)
|
|
td
|
66 (29)
|
|
td
|
20 (43)
|
|
td
|
91 (29)
|
|
tr
|
Below 10°C 19 (82) 19 (95) 163 (71) 26 (57) 227 (71)
|
|
td
|
Below 10°C
|
|
td
|
19 (82)
|
|
td
|
19 (95)
|
|
td
|
163 (71)
|
|
td
|
26 (57)
|
|
td
|
227 (71)
|
|
tr
|
Body site affected
|
|
td
|
Body site affected
|
|
tr
|
Foot 20 (87) 19 (95) 216 (94) 43 (93) 298 (94)
|
|
td
|
Foot
|
|
td
|
20 (87)
|
|
td
|
19 (95)
|
|
td
|
216 (94)
|
|
td
|
43 (93)
|
|
td
|
298 (94)
|
|
tr
|
Hand 7 (30) 2 (10) 31 (14) 8 (17) 48 (15)
|
|
td
|
Hand
|
|
td
|
7 (30)
|
|
td
|
2 (10)
|
|
td
|
31 (14)
|
|
td
|
8 (17)
|
|
td
|
48 (15)
|
|
tr
|
Dermatologic symptoms
|
|
td
|
Dermatologic symptoms
|
|
tr
|
Asymptomatic 4 (17) 2 (10) 24 (11) 6 (13) 36 (11)
|
|
td
|
Asymptomatic
|
|
td
|
4 (17)
|
|
td
|
2 (10)
|
|
td
|
24 (11)
|
|
td
|
6 (13)
|
|
td
|
36 (11)
|
|
tr
|
Pain/burning 16 (70) 16 (80) 144 (63) 35 (76) 211 (66)
|
|
td
|
Pain/burning
|
|
td
|
16 (70)
|
|
td
|
16 (80)
|
|
td
|
144 (63)
|
|
td
|
35 (76)
|
|
td
|
211 (66)
|
|
tr
|
Pruritus 8 (35) 9 (45) 99 (43) 21 (46) 137 (43)
|
|
td
|
Pruritus
|
|
td
|
8 (35)
|
|
td
|
9 (45)
|
|
td
|
99 (43)
|
|
td
|
21 (46)
|
|
td
|
137 (43)
|
|
tr
|
Cold intolerance 2 (8.7) 2 (10) 17 (7.4) 1 (2.2) 22 (6.9)
|
|
td
|
Cold intolerance
|
|
td
|
2 (8.7)
|
|
td
|
2 (10)
|
|
td
|
17 (7.4)
|
|
td
|
1 (2.2)
|
|
td
|
22 (6.9)
|
|
tr
|
Timing of dermatologic changes
|
|
td
|
Timing of dermatologic changes
|
|
tr
|
Before COVID-19 symptoms 4 (17) 0 (0.0) 12 (5.4) 3 (6.5) 19 (6.1)
|
|
td
|
Before COVID-19 symptoms
|
|
td
|
4 (17)
|
|
td
|
0 (0.0)
|
|
td
|
12 (5.4)
|
|
td
|
3 (6.5)
|
|
td
|
19 (6.1)
|
|
tr
|
After COVID-19 symptoms 11 (48) 6 (30) 48 (22) 15 (33) 80 (26)
|
|
td
|
After COVID-19 symptoms
|
|
td
|
11 (48)
|
|
td
|
6 (30)
|
|
td
|
48 (22)
|
|
td
|
15 (33)
|
|
td
|
80 (26)
|
|
tr
|
At the same time as COVID-19 3 (13) 1 (5.0) 14 (6.3) 4 (8.7) 22 (7.1)
|
|
td
|
At the same time as COVID-19
|
|
td
|
3 (13)
|
|
td
|
1 (5.0)
|
|
td
|
14 (6.3)
|
|
td
|
4 (8.7)
|
|
td
|
22 (7.1)
|
|
tr
|
No other COVID-19 symptoms 5 (22) 12 (60) 132 (59) 21 (46) 170 (55)
|
|
td
|
No other COVID-19 symptoms
|
|
td
|
5 (22)
|
|
td
|
12 (60)
|
|
td
|
132 (59)
|
|
td
|
21 (46)
|
|
td
|
170 (55)
|
|
tr
|
Unknown 0 (0.0) 1 (5.0) 17 (7.6) 3 (6.5) 21 (6.7)
|
|
td
|
Unknown
|
|
td
|
0 (0.0)
|
|
td
|
1 (5.0)
|
|
td
|
17 (7.6)
|
|
td
|
3 (6.5)
|
|
td
|
21 (6.7)
|
|
tr
|
COVID-19 exposure
|
|
td
|
COVID-19 exposure
|
|
tr
|
None (community acquired) 7 (30) 0 (0.0) 126 (55) 20 (43) 153 (48)
|
|
td
|
None (community acquired)
|
|
td
|
7 (30)
|
|
td
|
0 (0.0)
|
|
td
|
126 (55)
|
|
td
|
20 (43)
|
|
td
|
153 (48)
|
|
tr
|
Close contact with patient with
|
|
td
|
Close contact with patient with
|
|
tr
|
Confirmed COVID-19 3 (13) 20 (100) 0 (0.0) 1 (2.1) 24 (7.5)
|
|
td
|
Confirmed COVID-19
|
|
td
|
3 (13)
|
|
td
|
20 (100)
|
|
td
|
0 (0.0)
|
|
td
|
1 (2.1)
|
|
td
|
24 (7.5)
|
|
tr
|
Suspected COVID-19 8 (35) 4 (20) 26 (11) 6 (13) 44 (14)
|
|
td
|
Suspected COVID-19
|
|
td
|
8 (35)
|
|
td
|
4 (20)
|
|
td
|
26 (11)
|
|
td
|
6 (13)
|
|
td
|
44 (14)
|
|
tr
|
Presence in a health care facility where COVID-19 infections have been managed 1 (4.3) 0 (0.0) 10 (4.4) 7 (15) 18 (5.7)
|
|
td
|
Presence in a health care facility where COVID-19 infections have been managed
|
|
td
|
1 (4.3)
|
|
td
|
0 (0.0)
|
|
td
|
10 (4.4)
|
|
td
|
7 (15)
|
|
td
|
18 (5.7)
|
|
tr
|
COVID-19 symptoms
|
|
td
|
COVID-19 symptoms
|
|
tr
|
Asymptomatic 5 (22) 10 (50) 140 (61) 19 (41) 174 (55)
|
|
td
|
Asymptomatic
|
|
td
|
5 (22)
|
|
td
|
10 (50)
|
|
td
|
140 (61)
|
|
td
|
19 (41)
|
|
td
|
174 (55)
|
|
tr
|
Cough 9 (39) 3 (15) 41 (18) 14 (30) 67 (21)
|
|
td
|
Cough
|
|
td
|
9 (39)
|
|
td
|
3 (15)
|
|
td
|
41 (18)
|
|
td
|
14 (30)
|
|
td
|
67 (21)
|
|
tr
|
Headache 7 (30) 4 (20) 27 (12) 9 (20) 47 (15)
|
|
td
|
Headache
|
|
td
|
7 (30)
|
|
td
|
4 (20)
|
|
td
|
27 (12)
|
|
td
|
9 (20)
|
|
td
|
47 (15)
|
|
tr
|
Sore throat 5 (22) 4 (20) 21 (9.2) 8 (17) 38 (12)
|
|
td
|
Sore throat
|
|
td
|
5 (22)
|
|
td
|
4 (20)
|
|
td
|
21 (9.2)
|
|
td
|
8 (17)
|
|
td
|
38 (12)
|
|
tr
|
Fever 9 (39) 1 (5.0) 18 (7.9) 9 (20) 37 (12)
|
|
td
|
Fever
|
|
td
|
9 (39)
|
|
td
|
1 (5.0)
|
|
td
|
18 (7.9)
|
|
td
|
9 (20)
|
|
td
|
37 (12)
|
|
tr
|
Malaise 4 (17) 1 (5.0) 20 (8.7) 6 (13) 31 (9.7)
|
|
td
|
Malaise
|
|
td
|
4 (17)
|
|
td
|
1 (5.0)
|
|
td
|
20 (8.7)
|
|
td
|
6 (13)
|
|
td
|
31 (9.7)
|
|
tr
|
Shortness of breath 6 (26) 1 (5.0) 16 (7.0) 6 (13) 29 (9.1)
|
|
td
|
Shortness of breath
|
|
td
|
6 (26)
|
|
td
|
1 (5.0)
|
|
td
|
16 (7.0)
|
|
td
|
6 (13)
|
|
td
|
29 (9.1)
|
|
tr
|
COVID-19 level of care
|
|
td
|
COVID-19 level of care
|
|
tr
|
Outpatient care only 18 (78) 20 (100) 229 (100) 45 (98) 312 (98)
|
|
td
|
Outpatient care only
|
|
td
|
18 (78)
|
|
td
|
20 (100)
|
|
td
|
229 (100)
|
|
td
|
45 (98)
|
|
td
|
312 (98)
|
|
tr
|
Hospitalized, alive 3 (13) … … 1 (2.2) 4 (1.3)
|
|
td
|
Hospitalized, alive
|
|
td
|
3 (13)
|
|
td
|
…
|
|
td
|
…
|
|
td
|
1 (2.2)
|
|
td
|
4 (1.3)
|
|
tr
|
Hospitalized, died 2 (8.7) … … … 2 (0.6)
|
|
td
|
Hospitalized, died
|
|
td
|
2 (8.7)
|
|
td
|
…
|
|
td
|
…
|
|
td
|
…
|
|
td
|
2 (0.6)
|
|
tr
|
Comorbid medical conditions
|
|
td
|
Comorbid medical conditions
|
|
tr
|
None 17 (74) 12 (60) 172 (75) 36 (78) 237 (75)
|
|
td
|
None
|
|
td
|
17 (74)
|
|
td
|
12 (60)
|
|
td
|
172 (75)
|
|
td
|
36 (78)
|
|
td
|
237 (75)
|
|
tr
|
Obstructive lung disease 2 (8.7) 2 (10) 12 (5.2) 1 (2.2) 17 (5.3)
|
|
td
|
Obstructive lung disease
|
|
td
|
2 (8.7)
|
|
td
|
2 (10)
|
|
td
|
12 (5.2)
|
|
td
|
1 (2.2)
|
|
td
|
17 (5.3)
|
|
tr
|
Hypertension 2 (8.7) 1 (5.0) 5 (2.2) 1 (2.2) 9 (2.8)
|
|
td
|
Hypertension
|
|
td
|
2 (8.7)
|
|
td
|
1 (5.0)
|
|
td
|
5 (2.2)
|
|
td
|
1 (2.2)
|
|
td
|
9 (2.8)
|
|
tr
|
Rheumatologic disease 2 (8.7) … 3 (1.3) 3 (6.5) 8 (2.5)
|
|
td
|
Rheumatologic disease
|
|
td
|
2 (8.7)
|
|
td
|
…
|
|
td
|
3 (1.3)
|
|
td
|
3 (6.5)
|
|
td
|
8 (2.5)
|
|
tr
|
Inflammatory bowel disease … … 6 (2.6) 1 (2.2) 7 (2.2)
|
|
td
|
Inflammatory bowel disease
|
|
td
|
…
|
|
td
|
…
|
|
td
|
6 (2.6)
|
|
td
|
1 (2.2)
|
|
td
|
7 (2.2)
|
|
table-wrap-foot
|
PCR, Polymerase chain reaction.
|
|
footnote
|
PCR, Polymerase chain reaction.
|
|
p
|
PCR, Polymerase chain reaction.
|
|
table-wrap-foot
|
∗ Data are presented as number (%) or as median (interquartile range).
|
|
footnote
|
∗ Data are presented as number (%) or as median (interquartile range).
|
|
label
|
∗
|
|
p
|
Data are presented as number (%) or as median (interquartile range).
|
|
table-wrap-foot
|
† Two patients were COVID-19 antibody positive but polymerase PCR negative.
|
|
footnote
|
† Two patients were COVID-19 antibody positive but polymerase PCR negative.
|
|
label
|
†
|
|
p
|
Two patients were COVID-19 antibody positive but polymerase PCR negative.
|
|
table-wrap-foot
|
‡ One patient in this group had close contact with a COVID-19 laboratory positive patient.
|
|
footnote
|
‡ One patient in this group had close contact with a COVID-19 laboratory positive patient.
|
|
label
|
‡
|
|
p
|
One patient in this group had close contact with a COVID-19 laboratory positive patient.
|
|
table-wrap-foot
|
§ Defined as sex assigned at birth.
|
|
footnote
|
§ Defined as sex assigned at birth.
|
|
label
|
§
|
|
p
|
Defined as sex assigned at birth.
|
|
table-wrap-foot
|
‖ Calculated using state monthly averages in the United States and country monthly averages for the other countries listed.
|
|
footnote
|
‖ Calculated using state monthly averages in the United States and country monthly averages for the other countries listed.
|
|
label
|
‖
|
|
p
|
Calculated using state monthly averages in the United States and country monthly averages for the other countries listed.
|
|
p
|
Laboratory testing confirmed 23 patients (7%) were COVID-19 positive, including 13 by polymerase chain reaction (PCR) alone, 5 by antibody testing alone, 1 by combined PCR and antibody testing, and 4 by unknown assay. Of the 5 patients confirmed by antibody testing alone, 2 were immunoglobulin (Ig)M positive and IgG negative, with other patients' antibodies not specified. The 2 IgM-positive and IgG-negative antibody-confirmed patients both tested negative by PCR. PCR testing was not available for the other 3 antibody-positive patients. In addition, 20 patients had close contact with patients with confirmed COVID-19 (eg, child of health care worker who tested positive); though in 1 case, the patient subsequently tested PCR negative for COVID-19. Most cases (72%) were in patients with suspected COVID-19 without confirmatory testing at a time with limited testing access due to current testing criteria. These cases represent novel cases of new-onset pernio in patients without prior history, temporally associated with high levels of undetected community-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulation during the COVID-19 pandemic. Some patients who did receive testing had negative results: of 318 patients with pernio-like lesions, 46 were PCR negative and 14 were antibody negative.
|
|
p
|
Other COVID-19 symptoms were present in 45% of patients with pernio-like lesions. The most common were cough (21%), headache (15%), sore throat (12%), and fever (12%). When symptoms were present, the pernio-like lesions occurred before (13%), at the same time (15%), or after (54%) the COVID-19 symptoms. Patients generally had mild COVID-19 clinical courses, with 6 patients hospitalized, 2 of whom died. Of the 4 surviving hospitalized patients, 2 had uncomplicated courses, 1 patient required supplemental oxygen, and 1 required invasive mechanical ventilation. For 42 patients with the full course of pernio observed by providers, the lesions lasted for a median of 14 days (interquartile range, 10-21 days).
|
|
p
|
Pernio-like lesions affected only the feet in 84% of patients, only the hands in 5.1%, and a combination of the hands and feet in 10% (Fig 1 ). Associated acrocyanosis was seen in 9.2% and acral desquamation in 4.4%. Notably, 29% of patients lived in geographic regions with average March 2020 temperatures above 10°C, temperatures at which idiopathic pernio is less likely.
Fig 1 Pernio-like lesions on the (A-F) toes and (G) fingers in (A, C, D, E) COVID-19 polymerase chain reaction-positive patients, (E, F) antibody-positive patients, and (B, G) close contacts of COVID-19 polymerase chain reaction-positive patients.
|
|
figure
|
Fig 1 Pernio-like lesions on the (A-F) toes and (G) fingers in (A, C, D, E) COVID-19 polymerase chain reaction-positive patients, (E, F) antibody-positive patients, and (B, G) close contacts of COVID-19 polymerase chain reaction-positive patients.
|
|
label
|
Fig 1
|
|
caption
|
Pernio-like lesions on the (A-F) toes and (G) fingers in (A, C, D, E) COVID-19 polymerase chain reaction-positive patients, (E, F) antibody-positive patients, and (B, G) close contacts of COVID-19 polymerase chain reaction-positive patients.
|
|
p
|
Pernio-like lesions on the (A-F) toes and (G) fingers in (A, C, D, E) COVID-19 polymerase chain reaction-positive patients, (E, F) antibody-positive patients, and (B, G) close contacts of COVID-19 polymerase chain reaction-positive patients.
|
|
p
|
Dermatopathology was available for 1 PCR-positive patient, demonstrating mild vacuolar interface dermatitis with dense superficial and deep lymphocytic inflammation, consistent with pernio vs connective tissue disease. No thrombi were noted. Six other pathology reports from patients without laboratory confirmation showed findings consistent with pernio-like changes: (1) 1 with mild spongiosis, vacuolar interface change, few apoptotic epidermal keratinocytes, and perivascular and perieccrine lymphoid infiltrate, (2) 3 reporting superficial and deep perivascular, perieccrine lymphocytic or lymphohistiocytic infiltrate, without evidence of vasculitis, (3) 1 reporting a subepidermal blister with small vessel lymphocytic vasculitis without microthrombi, and (4) 1 reporting lymphocytic vasculitis with rare microthrombi and overlying epidermal necrosis.
|
|
sec
|
Discussion
Our registry-based, international collaborative series of patients presents the largest and most comprehensive collection of cases reported of pernio-like lesions as a cutaneous manifestation of confirmed or suspected COVID-19. Based on these data, we propose that this finding should prompt evaluation for the active or convalescent phase of infection. Patients in this case series were generally young, with few comorbidities, and had benign clinical courses. The pernio-like lesions in most patients developed either concurrently with, or after, COVID-19 symptoms, although 174 patients with confirmed or suspected COVID-19 presented only with pernio-like skin lesions. Given these findings, at a time when there continues to be significant undetected community-based SARS-CoV-2 transmission, we propose that pernio-like lesions should be considered in testing criteria for COVID-19, with larger population-based epidemiologic studies needed to confirm or refute this association.
Given evolving understanding of COVID-19, clear public health messaging regarding these pernio-like lesions is paramount. A key implication of COVID-19 cutaneous manifestations is the opportunity to recognize patients, especially asymptomatic ones, who are at risk for spreading infection. The fact that many of our patients were otherwise asymptomatic and had not been tested for COVID-19 likely reflects limited availability of COVID-19 PCR testing at the start of the United States outbreak and variable state-by-state and country-by-country testing regulations. In many locations, testing has been limited to sicker patients, selecting against testing of patients with mild disease, including those who may develop COVID-19–associated pernio-like skin lesions.
Also important is our ability to reassure the public regarding the relatively benign clinical course observed in most of our patients. Lesions in this series resolved in a median of 2 weeks. This duration is likely an underestimate, because the clinical courses of many patients are ongoing, and the data were only available for patients with completed disease courses.
Questions remain about patients who presented with pernio-like changes and presumed COVID-19 who were ultimately PCR negative. Explanations for these patients include (1) findings were not COVID-19-related, (2) false-negative test results, or (3) testing occurred after viral clearance, with pernio-like lesions representing a late clinical finding. Although multiple possibilities exist, reports from Europe of pernio-like lesions during the COVID-19 surge suggest a true association,1 , 4 , 5 with pernio-like findings most commonly appearing in younger patients and later in the disease course.1
New developments in COVID-19 antibody testing may further clarify the timing of pernio-like lesions in the COVID-19 clinical course. Of the 20 patients known to have antibody testing (IgM, IgG, unspecified, or both), only 6 (30%) tested positive. Two of these patients were PCR negative but IgM positive. Early studies have suggested that for antibody response to SARS-CoV-2, IgM peaks at day 28 whereas IgG peaks at day 49 after the onset of illness.7 Although there is a possibility that IgM positivity represents a false positive, if reliable, it instead supports the theory that antibody testing would be an important part of the evaluation of pernio-like lesions to rule out COVID-19. Further, if pernio is indeed a later disease course phenomenon in at least a subset of patients, then it may be prudent to repeat antibody testing and/or seek delayed IgG testing for suspected patients.
We must critically examine with further investigation why some patients with COVID-19–associated pernio-like lesions might test negative with current antibody testing. Immunocompromised patients may fail to generate antibodies, but most patients with COVID-19–associated pernio-like lesions are otherwise healthy young patients whose skin lesions developed late in their course with theoretically sufficient time to generate IgM or IgG antibodies, or both.
There are several possible explanations. Certainly, some patients may have new-onset pernio from other non–COVID-19 causes. That may be true for some of these patients, but given the large number of new reports of pernio coincidentally with the COVID-19 pandemic, it is unlikely to explain all cases. Some patients in the registry with negative antibodies had clinical histories predictive of high pretest probability; for example, a physician caring for COVID-19 patients in Milan and a child with a PCR-positive parent. One possibility is false-negative test results, because there is significant variability in the sensitivity and specificity of current tests on the market.8 , 9 It is also possible that many patients with COVID-19 may have a delayed antibody responses. Another, more worrisome, explanation is that the antibody response in patients with relatively mild disease tends not to be as brisk.7 , 10 This explanation is concerning, because it would both question the validity of our current antibody testing and suggest that patients with mild or asymptomatic disease may not generate antibodies (and possible immunity) upon infection with SARS-Cov-2. Finally, reliable testing combined with coordination of timing of these skin changes with COVID-19 PCR, IgG, and IgM testing results is imperative to better establish self-isolation recommendations for patients presenting with pernio-like lesions.
There are multiple potential pathophysiologic mechanisms underpinning pernio-like lesions in COVID-19. In nonepidemic settings, pernio is often idiopathic or related to underlying disease (eg, systemic lupus erythematosus or antiphospholipid antibody syndrome), and cannot easily be ascertained with histopathology alone.11 The histopathology reported for 1 of the COVID-19 PCR-positive patients, as well as 4 of 6 patients with suspected COVID-19, demonstrated features consistent with pernio without evidence of vascular damage, suggesting COVID-19–associated pernio-like lesions may be simply inflammatory. The other 2 of 6 patients with suspected COVID-19 with histopathology reported vascular changes, including lymphocytic vasculitis, which can sometimes be seen in conjunction with variants of pernio. Indeed, interferon response to viral infection appears to be a clue why some patients do poorly while others fare well.12 , 13
Less likely, but worthy of consideration, is that prothrombotic coagulopathy may be a contributing factor, as suggested by COVID-19 cases complicated by venous thromboembolism, pathologic reports of microvascular thrombosis,14 and laboratory abnormalities including elevated D-dimer and high fibrinogen.15, 16, 17 Furthermore, antiphospholipid antibodies have been implicated in a small case series of patients acutely ill with COVID-1918 and have previously been associated with pernio. With greater clinical and pathologic correlation, we hope to better understand the pathophysiology, including understanding how, if at all, hypercoagulability plays a role in COVID-19–associated pernio-like lesions. Importantly, although young patients with COVID-19 have presented with stroke, we are not aware of any cases of concomitant pernio-like lesions and strokes.19
Limitations of this case series include incomplete testing for COVID-19, especially in otherwise asymptomatic patients. We are also unable to estimate the incidence or prevalence of this condition. There may be confirmation bias in reporting of cases. In addition, the background incidence of pernio from other causes in March and April is not well documented.6 We cannot exclude an epiphenomenon, because this case series cannot establish causation. Future studies are needed to assess the histopathology of pernio-like lesions to inform understanding of the disease process.
|
|
title
|
Discussion
|
|
p
|
Our registry-based, international collaborative series of patients presents the largest and most comprehensive collection of cases reported of pernio-like lesions as a cutaneous manifestation of confirmed or suspected COVID-19. Based on these data, we propose that this finding should prompt evaluation for the active or convalescent phase of infection. Patients in this case series were generally young, with few comorbidities, and had benign clinical courses. The pernio-like lesions in most patients developed either concurrently with, or after, COVID-19 symptoms, although 174 patients with confirmed or suspected COVID-19 presented only with pernio-like skin lesions. Given these findings, at a time when there continues to be significant undetected community-based SARS-CoV-2 transmission, we propose that pernio-like lesions should be considered in testing criteria for COVID-19, with larger population-based epidemiologic studies needed to confirm or refute this association.
|
|
p
|
Given evolving understanding of COVID-19, clear public health messaging regarding these pernio-like lesions is paramount. A key implication of COVID-19 cutaneous manifestations is the opportunity to recognize patients, especially asymptomatic ones, who are at risk for spreading infection. The fact that many of our patients were otherwise asymptomatic and had not been tested for COVID-19 likely reflects limited availability of COVID-19 PCR testing at the start of the United States outbreak and variable state-by-state and country-by-country testing regulations. In many locations, testing has been limited to sicker patients, selecting against testing of patients with mild disease, including those who may develop COVID-19–associated pernio-like skin lesions.
|
|
p
|
Also important is our ability to reassure the public regarding the relatively benign clinical course observed in most of our patients. Lesions in this series resolved in a median of 2 weeks. This duration is likely an underestimate, because the clinical courses of many patients are ongoing, and the data were only available for patients with completed disease courses.
|
|
p
|
Questions remain about patients who presented with pernio-like changes and presumed COVID-19 who were ultimately PCR negative. Explanations for these patients include (1) findings were not COVID-19-related, (2) false-negative test results, or (3) testing occurred after viral clearance, with pernio-like lesions representing a late clinical finding. Although multiple possibilities exist, reports from Europe of pernio-like lesions during the COVID-19 surge suggest a true association,1 , 4 , 5 with pernio-like findings most commonly appearing in younger patients and later in the disease course.1
|
|
p
|
New developments in COVID-19 antibody testing may further clarify the timing of pernio-like lesions in the COVID-19 clinical course. Of the 20 patients known to have antibody testing (IgM, IgG, unspecified, or both), only 6 (30%) tested positive. Two of these patients were PCR negative but IgM positive. Early studies have suggested that for antibody response to SARS-CoV-2, IgM peaks at day 28 whereas IgG peaks at day 49 after the onset of illness.7 Although there is a possibility that IgM positivity represents a false positive, if reliable, it instead supports the theory that antibody testing would be an important part of the evaluation of pernio-like lesions to rule out COVID-19. Further, if pernio is indeed a later disease course phenomenon in at least a subset of patients, then it may be prudent to repeat antibody testing and/or seek delayed IgG testing for suspected patients.
|
|
p
|
We must critically examine with further investigation why some patients with COVID-19–associated pernio-like lesions might test negative with current antibody testing. Immunocompromised patients may fail to generate antibodies, but most patients with COVID-19–associated pernio-like lesions are otherwise healthy young patients whose skin lesions developed late in their course with theoretically sufficient time to generate IgM or IgG antibodies, or both.
|
|
p
|
There are several possible explanations. Certainly, some patients may have new-onset pernio from other non–COVID-19 causes. That may be true for some of these patients, but given the large number of new reports of pernio coincidentally with the COVID-19 pandemic, it is unlikely to explain all cases. Some patients in the registry with negative antibodies had clinical histories predictive of high pretest probability; for example, a physician caring for COVID-19 patients in Milan and a child with a PCR-positive parent. One possibility is false-negative test results, because there is significant variability in the sensitivity and specificity of current tests on the market.8 , 9 It is also possible that many patients with COVID-19 may have a delayed antibody responses. Another, more worrisome, explanation is that the antibody response in patients with relatively mild disease tends not to be as brisk.7 , 10 This explanation is concerning, because it would both question the validity of our current antibody testing and suggest that patients with mild or asymptomatic disease may not generate antibodies (and possible immunity) upon infection with SARS-Cov-2. Finally, reliable testing combined with coordination of timing of these skin changes with COVID-19 PCR, IgG, and IgM testing results is imperative to better establish self-isolation recommendations for patients presenting with pernio-like lesions.
|
|
p
|
There are multiple potential pathophysiologic mechanisms underpinning pernio-like lesions in COVID-19. In nonepidemic settings, pernio is often idiopathic or related to underlying disease (eg, systemic lupus erythematosus or antiphospholipid antibody syndrome), and cannot easily be ascertained with histopathology alone.11 The histopathology reported for 1 of the COVID-19 PCR-positive patients, as well as 4 of 6 patients with suspected COVID-19, demonstrated features consistent with pernio without evidence of vascular damage, suggesting COVID-19–associated pernio-like lesions may be simply inflammatory. The other 2 of 6 patients with suspected COVID-19 with histopathology reported vascular changes, including lymphocytic vasculitis, which can sometimes be seen in conjunction with variants of pernio. Indeed, interferon response to viral infection appears to be a clue why some patients do poorly while others fare well.12 , 13
|
|
p
|
Less likely, but worthy of consideration, is that prothrombotic coagulopathy may be a contributing factor, as suggested by COVID-19 cases complicated by venous thromboembolism, pathologic reports of microvascular thrombosis,14 and laboratory abnormalities including elevated D-dimer and high fibrinogen.15, 16, 17 Furthermore, antiphospholipid antibodies have been implicated in a small case series of patients acutely ill with COVID-1918 and have previously been associated with pernio. With greater clinical and pathologic correlation, we hope to better understand the pathophysiology, including understanding how, if at all, hypercoagulability plays a role in COVID-19–associated pernio-like lesions. Importantly, although young patients with COVID-19 have presented with stroke, we are not aware of any cases of concomitant pernio-like lesions and strokes.19
|
|
p
|
Limitations of this case series include incomplete testing for COVID-19, especially in otherwise asymptomatic patients. We are also unable to estimate the incidence or prevalence of this condition. There may be confirmation bias in reporting of cases. In addition, the background incidence of pernio from other causes in March and April is not well documented.6 We cannot exclude an epiphenomenon, because this case series cannot establish causation. Future studies are needed to assess the histopathology of pernio-like lesions to inform understanding of the disease process.
|
|
sec
|
Conclusion
Our case series demonstrates pernio-like skin lesions as a manifestation of COVID-19. Patients with pernio-like lesions of COVID-19 may still be infectious and pose a public health risk, because skin lesions developed in at least 4 patients in this report before COVID-19 PCR confirmation, and the lesions developed in 14 while still PCR positive. We propose that pernio-like lesions be added to the testing criteria for COVID-19 and prompt consideration of testing for both PCR and IgM and IgG antibodies. This information will be critical to understanding the significance of these cutaneous lesions and empowering physicians and other health care providers to counsel patients appropriately.
|
|
title
|
Conclusion
|
|
p
|
Our case series demonstrates pernio-like skin lesions as a manifestation of COVID-19. Patients with pernio-like lesions of COVID-19 may still be infectious and pose a public health risk, because skin lesions developed in at least 4 patients in this report before COVID-19 PCR confirmation, and the lesions developed in 14 while still PCR positive. We propose that pernio-like lesions be added to the testing criteria for COVID-19 and prompt consideration of testing for both PCR and IgM and IgG antibodies. This information will be critical to understanding the significance of these cutaneous lesions and empowering physicians and other health care providers to counsel patients appropriately.
|
|
back
|
We would like to thank Drs Philippe Dieude, Cynthia Yalowitz, Rachel Hub, Emily Arch, Ambrose Su, and Haydee Knott for providing photographs, Drs Rina Allawh, Graeme Lipper, Lynda Kauls, Lee Albert, Shannon Keiser, and Sarah Smilow for providing pathology, Dr Mariko Yasuda for her input on pathophysiologic mechanisms, and Dr Marlys Fassett for her contributions regarding antibody testing. We would like to thank the American Academy of Dermatology Ad Hoc Task Force on COVID-19 and staff at the American Academy of Dermatology for their logistical and administrative support. We would like to thank the International League of Dermatological Societies for their international collaboration. We also appreciate the COVID-19 Global Rheumatology Alliance for sharing their experience with registry development. Funding sources: None.
Conflicts of interest: Drs Freeman, Lipoff, Rosenbach, Kovarik, Takeshita, Hruza, and Fox are part of the American Academy of Dermatology (AAD) Covid-19 Ad Hoc Task Force. Dr French is president of the International League of Dermatological Societies. Dr Hruza is immediate past president of the AAD. Dr Thiers is the president of the AAD. Author McMahon has no conflicts of interest to disclose.
IRB approval status: The registry was reviewed by the Partners Healthcare (Massachusetts General Hospital) Institutional Review Board and was determined to not meet the definition of Human Subjects Research.
Reprints not available from the authors.
|
|
ack
|
We would like to thank Drs Philippe Dieude, Cynthia Yalowitz, Rachel Hub, Emily Arch, Ambrose Su, and Haydee Knott for providing photographs, Drs Rina Allawh, Graeme Lipper, Lynda Kauls, Lee Albert, Shannon Keiser, and Sarah Smilow for providing pathology, Dr Mariko Yasuda for her input on pathophysiologic mechanisms, and Dr Marlys Fassett for her contributions regarding antibody testing. We would like to thank the American Academy of Dermatology Ad Hoc Task Force on COVID-19 and staff at the American Academy of Dermatology for their logistical and administrative support. We would like to thank the International League of Dermatological Societies for their international collaboration. We also appreciate the COVID-19 Global Rheumatology Alliance for sharing their experience with registry development.
|
|
p
|
We would like to thank Drs Philippe Dieude, Cynthia Yalowitz, Rachel Hub, Emily Arch, Ambrose Su, and Haydee Knott for providing photographs, Drs Rina Allawh, Graeme Lipper, Lynda Kauls, Lee Albert, Shannon Keiser, and Sarah Smilow for providing pathology, Dr Mariko Yasuda for her input on pathophysiologic mechanisms, and Dr Marlys Fassett for her contributions regarding antibody testing. We would like to thank the American Academy of Dermatology Ad Hoc Task Force on COVID-19 and staff at the American Academy of Dermatology for their logistical and administrative support. We would like to thank the International League of Dermatological Societies for their international collaboration. We also appreciate the COVID-19 Global Rheumatology Alliance for sharing their experience with registry development.
|
|
footnote
|
Funding sources: None.
|
|
p
|
Funding sources: None.
|
|
footnote
|
Conflicts of interest: Drs Freeman, Lipoff, Rosenbach, Kovarik, Takeshita, Hruza, and Fox are part of the American Academy of Dermatology (AAD) Covid-19 Ad Hoc Task Force. Dr French is president of the International League of Dermatological Societies. Dr Hruza is immediate past president of the AAD. Dr Thiers is the president of the AAD. Author McMahon has no conflicts of interest to disclose.
|
|
p
|
Conflicts of interest: Drs Freeman, Lipoff, Rosenbach, Kovarik, Takeshita, Hruza, and Fox are part of the American Academy of Dermatology (AAD) Covid-19 Ad Hoc Task Force. Dr French is president of the International League of Dermatological Societies. Dr Hruza is immediate past president of the AAD. Dr Thiers is the president of the AAD. Author McMahon has no conflicts of interest to disclose.
|
|
footnote
|
IRB approval status: The registry was reviewed by the Partners Healthcare (Massachusetts General Hospital) Institutional Review Board and was determined to not meet the definition of Human Subjects Research.
|
|
p
|
IRB approval status: The registry was reviewed by the Partners Healthcare (Massachusetts General Hospital) Institutional Review Board and was determined to not meet the definition of Human Subjects Research.
|
|
footnote
|
Reprints not available from the authors.
|
|
p
|
Reprints not available from the authors.
|
